Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy

Muscle and Nerve

Volumn 43, Issue 3, 2011, Pages 367-374

  Park, Susanna B ^a,b   Lin, Cindy S Y ^b   Krishnan, Arun V ^b   Friedlander, Michael L ^c   Lewis, Craig R ^c   Kiernan, Matthew C ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Chemotherapy; Excitability; Neurotoxicity; Paclitaxel; Peripheral neuropathy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; NERVE EXCITABILITY; NERVE FIBER; NEUROPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSORY ANALYSIS; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SYMPTOM;

ADULT; AXONS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MEMBRANE POTENTIALS; MIDDLE AGED; PACLITAXEL; POLYNEUROPATHIES; PROSPECTIVE STUDIES; SENSORY RECEPTOR CELLS; TIME FACTORS;

EID: 79951927821     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21874     Document Type: Article

References (58)

1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-2327.
2. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower, RC. Neurotoxicity of taxol. J Natl Cancer Inst Monogr 1993;15:107-115.
3. Michaud LB, Valero V, Hortobagvi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Safety 2000;23:401-428.
4. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. Taxanes as firstline therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005;50:355-374.
5. Schiff PB, Fant J, Horowitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-667. (Pubitemid 9114288)
6. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993;90:9552-9556. (Pubitemid 23315823)
7. Lück HJ, Roché H. Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Crit Rev Oncol Hematol 2002;44(suppl):S15-S30. (Pubitemid 36194424)
8. Nabholtz J-M, Gligorov J. The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother 2005;6:1073-1094. (Pubitemid 40959472)
9. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and Leukemia Group B Trial 9342. J Clin Oncol 2004;22:2061-2068. (Pubitemid 41095138)
10. Budman DR. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer. Semin Oncol 2004;31:3-9. (Pubitemid 40075511)
11. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with Trastuzumab for all HER-2 overexpressors and random assignment to Trastuzumab or not in HER-2 non overexpressors: final results of Cancer and Leukemia Group B Protocol 9840. J Clin Oncol 2008;26:1642-1649.
12. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Sapher T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-1671. (Pubitemid 351549913)
13. Sahenk Z, Barohn R, New P, Mendell, JR. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 1994;51: 726-729.
14. Einzig AI, Wiernik PH, Wadler S, Kaplan J, Benson LT, Tentoramano L, et al. Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy. Invest New Drugs 1998;16:29-36. (Pubitemid 28379413)
15. Stern KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer 2008;112(suppl): 2577-2592.
16. Blumenthal DT. Assessment of neuropathic pain in cancer patients. Curr Pain Headache Rep 2009;13:282-287.
17. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53:1660-1664. (Pubitemid 29530336)
18. Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007;12:210-215. (Pubitemid 47404378)
19. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ III. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42:1164-1170.
20. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005;32:51-60. (Pubitemid 40917889)
21. Kim BJ, Park HR, Roh HJ, Jeong DS, Kim BS, Park KW, et al. Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res 2010;19:1097-1103.
22. Kimura J. Electrodiagnosis in diseases of nerve and muscle. Philadelphia: F.A. Davis; 1983.
23. Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998;21:137-158. (Pubitemid 28079733)
24. Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000;23:399-409. (Pubitemid 30126986)
25. Kiernan MC, Lin CSY, Andersen KV, Murray NM, Bostock H. Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve 2001;24:883-892. (Pubitemid 32549971)
26. Krishnan AV, Lin CSY, Park SB, Kiernan MC. Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol 2009;89:288-313.
27. Brismar T. Changes in electrical threshold in human peripheral neuropathy. J Neurol Sci 1985;68:215-223. (Pubitemid 15031491)
28. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neuro-Oncol 1997;35: 47-53. (Pubitemid 27361845)
29. Augusto C, Pietro M, Cinzia M, Sergio C, Sara C, Luca G, et al. Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings. J Neuro-Oncol 2008;86:89-99. (Pubitemid 350263438)
30. Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000;123:2542-2551.
31. Meulstee J, Darbas A, van Doorn PA, van Briemen L, van der Meche FG. Decreased electrical excitability of peripheral nerves in demyelinating polyneuropathies. J Neurol Neurosurg Psychiatry 1997;62: 398-400. (Pubitemid 27199116)
32. Pace A, Nistico C, Cuppone F, Bria E, Galie E, Graziano G, et al. Peripheral neurotoxcity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer 2007;7:550-554.
33. Park SB, Lin CSY, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009;132: 2712-2723.
34. LoMonaco M, Milone M, Batocchi AP, Padua L, Restuccia D, Tonali P. Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 1992;239:199-204.
35. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004;29:387-392. (Pubitemid 38269758)
36. Park SB, Goldstein D, Lin CSY, Krishnan AV, Friedlander ML, Kiernan MC. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009;27:1243-1249.
37. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res 2006;12: 4481-4484. (Pubitemid 44297795)
38. Kiernan MC, Krishnan AV. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 2006;13:2901-2907. (Pubitemid 44509715)
39. Krishnan AV, Lin CS-Y, Park SB, Kiernan MC. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst 2008;13:7-26. (Pubitemid 351393017)
40. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994;35:304-311. (Pubitemid 24089653)
41. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 2004;15:1439-1442. (Pubitemid 39295034)
42. Pignata S, De Placido S, Biamonte R, Scambia G, Di Vagno G, Colucci G, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006;6:5.
43. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-5992.
44. Openshaw H, Beamon K, Synold TW, Longmate J, Slatkin NE, Doroshow JH, et al. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel. Clin Cancer Res 2004;10:461-467.
45. Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol 2001;112:1575-1585. (Pubitemid 32763239)
46. Van den Bent MJ, van Raaij-van den Aarssen VJ, Verweij J, Doorn PA, Sillevis Smitt PA. Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 1997;20: 750-752. (Pubitemid 27197731)
47. Gueritte F. General and recent aspects of the chemistry and structure activity relationships of taxoids. Curr Pharm Des 2001;7:1229-1249. (Pubitemid 32798806)
48. Nakata T, Yorifuji H. Morphological evidence of the inhibitory effect of taxol on the fast axonal transport. Neurosci Res 1999;35:113-122. (Pubitemid 29518402)
49. Theiss C, Meller K. Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res 2000;299:213-224. (Pubitemid 30103139)
50. Conde C, Cáceres A. Microtubule assembly, organization and dynamics in axons and dendrites. Nature Rev Neurosci 2009;10:319-332.
51. McLeod JG, Penny R. Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry 1969;32:297-304.
52. McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001;85:1219-1225. (Pubitemid 33052324)
53. Camdessanché JP, Jousserand G, Ferraud K, Vial C, Petiot P, Honnorat J, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain 2009;132:1723-1733.
54. Guiheneuc P, Ginet J, Groleau JY, Rojouan J. Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dyingback phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex. J Neurol Sci 1980;45:355-366. (Pubitemid 10133733)
55. Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy: clinical and electrophysiological observations. Brain 1973;96:69-86.
56. Wang MS, Davis AA, Culver DG, Wang Q, Powers JC, Glass JD. Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain 2004;127:671-679. (Pubitemid 38295480)
57. Flatters SJL, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006;122:245-257. (Pubitemid 43729476)
58. Shemesh O, Spira M. Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol 2009;119:235-248.